Cat. No. |
Product Name |
Information |
PC-21940 |
UNC1999
EZH2 inhibitor
|
UNC1999 is a potent, selectice SAM-competitive and orally bioavailable inhibitor of EZH2/EZH1 with IC50 of <10 nM/45 nM, respectively. |
PC-21939 |
GSK126
EZH2 inhibitor
|
GSK126 (GSK2816126A) is a potent, highly selective, and SAM-competitive inhibitor of EZH2 methyltransferase with IC50 of 9.9 nM. |
PC-21938 |
Tazemetostat
EZH2 inhibitor
|
Tazemetostat (EPZ-6438) is a potent, selective, SMA-competitive and orally available EZH2 inhibitor with IC50 of 11 and 16 nM in peptide assay and nucleosome assay, respectively. |
PC-21930 |
CPI-360
EZH2 inhibitor
|
CPI-360 is a potent, selective EZH2 inhibitor with IC50 of 0.5 and 2.5 nM for wild-type EZH2 and Y641N mutant EZH2, respectively. |
PC-21857 |
BI-9321 trihydrochloride
NSD3 inhibitor
|
BI-9321 (BI 9321) trihydrochloride is a potent, selective and cellular active inhibitor of the NSD3-PWWP1 domain with SPR Kd of 166 nM. |
PC-21842 |
GSK3368715 dihydrochloride
Type 1 PRMT inhibitor
|
GSK3368715 (EPZ019997, GSK-3368715) dihydrochloride is a potent, reversible and SAM uncompetitive type I PRMT inhibitor with Kiapp of 1.5 to 81 nM for PRMT1, 3, 4, 6, and 8. |
PC-21832 |
WDR5 WBM site inhibitor 7k
WDR5 WBM site inhibitor
|
WDR5 WBM site inhibitor 7k is a selective small molecule inhibitor of WDR5 WBM binding site with Ki of 107 nM, inhibits lncRNA-WDR5 complex formation. |
PC-21619 |
EPZ004777
DOT1L inhibitor
|
EPZ004777 is a potent, selective inhibitor of DOT1L with Ki of 0.3 nM and IC50 of 0.4 nM, selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. |
PC-21618 |
Pinometostat
DOT1L inhibitor
|
Pinometostat (EPZ-5676) is a potent and selective inhibitor of DOT1L histone methyltransferase activity with Ki of 0.08 nM, 37000-fold selectivity over other methyltransferases. |
PC-21606 |
KMI169
KMT9 inhibitor
|
KMI169 (KMI-169) is a potent and selective lysine methyltransferase 9 (KMT9) inhibitor with ITC Kd of 25 nM and enzymatic IC50 of 50 nM. |
PC-21568 |
BN104
menin-MLL inhibitor
|
BN104 (BNM-1192) is a potent, highly selective small molecule menin-MLL inhibitor, BNM-1192 is very potent against leukemia cell lines with MLL-fusion protein and NPM1 mutant (MV-4-11 (AF4 fusion), IC50=3.5 nM). |
PC-21491 |
DP308
53BP1 inhibitor
|
DP308 is a novel and effective 53BP1 tandem Tudor domain (TTD) inhibitor, disrupts the binding between 53BP1 and H4K20me2 peptide with IC50 of 1.69 uM. |